As part of our mission to eliminate cancer, Torrance Memorial Hunt Cancer Institute physicians conduct several clinical trials to test new treatments for both common and rare cancers. Look through our clinical trials list to find studies for which you may be eligible.

Hunt Cancer Institute Active Clinical Trials

These studies are currently enrolling participants.

Disease Title Summary Status Investigator
Breast Cancer neoMonarch Lilly JPBY Breast Cancer A preoperative endocrine study for postmenopausal hormone receptor positive breast cancer evaluating the effectiveness of adding a CKD4/6 inhibitor to standard anastrozole (Arimidex). For 4 months before surgery. CKD4/6 inhibitors are active in increasing benefits of aromatase inhibitors in stage 4 breast cancer. Aromatase inhibitors given before surgery result in smaller cancers and lower mastectomy rates. Open/Active David Chan, M.D.
Breast Cancer PUMA NER-6201 Breast Cancer Neritinib is a experimental 2nd generation oral HER2 targeting drug that has reduced relapsed rate after HER2 based chemotherapy in early breast cancer. Patients receive neritinib for one year to monitor tolerance and side effects. Open/Active David Chan, M.D.
Breast Cancer Novartis CLEE011E2301 (MONALEESA-7) Breast Cancer A Phase 3 randomized study of LEE011, a new CDK4/6 inhibitor with tamoxifen or an aromatase inhibitor in combination with goserelin in the treatment of premenopausal hormone receptor positive, HER2-negative, advanced breast cancer. This study evaluates the effectiveness of an experimental targeted drug in improving the endocrine treatment. Open/Active David Chan, M.D.
Breast Cancer TRIO-US B-10 Breast Cancer A phase 2 randomized trial of MuGard for prevention and treatment of mouthsores in women with hormone receptor positive breast cancer receiving treatment with everolimus-endocrine therapy. Afinitor is often used in combination with Aromasin in stage 4 breast cancer. Patients often have uncomfortable mouth sores. This study assesses Mugard in reducing mucositis. Open/Active David Chan, M.D.
Breast Cancer GNE GO29227 (LOTUS) Breast Cancer A randomized Phase 2 multicenter study of ipatasertib (GDC-0068), an inhibitor of AKT, in combination with paclitaxel as first-line treatment for patients with metastatic triple-negative breast cancer. Triple negative breast cancers are ER, PR and HER2 negative. The AKT pathway is targeted in this study. Open/Active David Chan, M.D.
Breast Cancer Clovis CO-3810-025 (LUCY) Breast Cancer A Phase 2 multicenter study of oral lucitanib in patients with FGF aberrant metastatic breast cancer. About 15% of breast cancers have the FGFR pathway. This study uses an oral targeted drug to attack that pathway. Open/Active David Chan, M.D.
Breast Cancer Biomarin BMN 673-301/201 (EMBRACA) Breast Cancer A Phase 3 randomized multi-center study of BMN 673 versus Physician’s Choice in BRCA positive with locally advanced or metastatic breast cancer, who have received no more than 2 prior chemotherapy regimens. BMN 673 is an oral PARP inhibitor and PARP pathway is important in BRCA related breast cancers. Open/Active David Chan, M.D.
Breast Cancer

TRIO 020 Breast Cancer

 A randomized phase 2 trial of letrozole plus afatinib versus letrozole alone in postmenopausal hormone receptor positive, HER2 negative patients with metastatic disease with low ER expression. Afatinib is approved to treat EGFR positive lung cancer and has activity in breast cancer. Open/Active David Chan, M.D.
Breast Cancer Merrimack MM-302-02-02-03 Breast Cancer A randomized multicenter study of MM-302 plus trastuzumab vs. standard chemotherapy plus trastuzumab in anthracycline naïve patients with locally advanced/metastatic HER2-Positive breast cancer. MM-302 is a new encapsulated anthracycline that targets the HER2 protein. Open/Active David Chan, M.D.
Breast Cancer TRIO-US B-09 Breast Cancer Phase 1b/2 trial evaluating the combination of lapatinib, everolimus and capecitabine for the treatment of patients with HER2-positive metastatic breast cancer with CNS progression after trastuzumab. This study evaluates the effective of using 3 oral drugs in treating HER2 positive breast cancer with brain involvement. Open/Active David Chan, M.D.
Breast Cancer PUMA NER 1301 (NALA) Breast Cancer A study of neratinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer who have received two or more prior HER2-directed regimens in the metastatic setting. This study evaluates 2 oral combinations targeting HER2 in stage 4 breast cancer. Open/Active David Chan, M.D.
Breast Cancer Genomic Health 14-002/Breast Cancer A national multicenter feasibility study to develop a molecular blood test that could accurately assess the status of breast cancer patients and their response to treatment. Open/Active David Chan, M.D.
GI Cancer Lilly I4T-MC-JVCU (RAINFALL) Gastric Cancer A randomized Phase 3 Study of capecitabine and cisplatin with or without ramucirumab in first-line therapy of patients with metastatic gastric/GE junction adenocarcinoma. This study evaluates a 2nd generation angiogenesis inhibitor in combination with standard chemotherapy for stage 4 cancers of the stomach and lower esophagus. Open/Active Hugo Hool, M.D.
GI Cancer Merrimack 141-07-02-02 (CARRIE) Pancreatic Cancer A randomized Phase 2 Study of MM-141 used in combination with Abraxane and Gemzar in 1st line metastatic pancreatic cancer. The study drug is a bi-specific antibody attacking the IGF pathway. Open/Active Hugo Hool, M.D.
GI Cancer Incyte INCB 18424-362 (JANUS1) Pancreatic Cancer A randomized Phase 3 Study of the JAK1/2 Inhibitor, ruxolitinib in combination with capecitabine in advanced or metastatic cancer of the pancreas who have already had one round of chemotherapy. This 2nd line regimen uses all oral drugs. Open/Active Hugo Hool, M.D.
Lung Cancer AstraZeneca D419A (MYSTIC) NSCLC A phase 3 trial comparing standard platinum based chemotherapy with the addition of single or double immunotherapies with experimental checkpoint inhibitors. This is a key study in moving checkpoint inhibitors earlier in the treatment cycle. Open/Active Thomas Lowe, M.D.
Lung Cancer Clovis CO-1686-020 (TIGER 3) NSCLC A Phase 3 multicenter randomized Study of oral CO-1686 versus single chemotherapy in patients with mutant EGFR non-small cell lung cancer (NSCLC) after previous treatment with EGFR-directed tyrosine kinase inhibitor (TKI) and a platinum doublet chemotherapy. This study evaluates a next generation oral inhibitor of EGFR. Open/Active Thomas Lowe, M.D.
Lung Cancer Lilly I3Y-MC-JPBK (JUNIPER) NSCLC A Randomized Phase 3 Study of abemaciclib versus Erlotinib in patients with Stage IV NSCLC with a detectable KRAS Mutation who have progressed after platinum-based chemotherapy. The study drug is a new CDK4/6 inhibitor. Open/Active Thomas Lowe, M.D.
Lung Cancer AVEO AV-299 NSCLC A Phase 2 randomized study for EGFR positive (19 or 21) VeriStrat serum biomarker “good”. All patients recieve Tarceva and can be selected to also receive ficlatuzuamb, an antibody directed against hepatocyte growth factor, HGF. Open/Active Andrew Horodner, M.D.
Head and Neck Cancer AstraZeneca D4193 (HAWK) This is an immunotherapy trial. MED1476 is an experimental antibody checkpoint inhibitor that results in immune destruction across a wide range of cancers. Patients who have relapsed after previous radiation and chemotherapy are eligible. Open/Active Thomas Lowe, M.D.
Head and Neck Cancer AstraZeneca D4193 (Eagle 02) This study evaluates two checkpoint inhibitors that promote the immune system to eradicate cancer. MED1476 alone, or paired with tremelimumab is compared with best standard chemotherapy. Open/Active Thomas Lowe, M.D.
Head and Neck Cancer AstraZeneca D4193 (CONDOR) This is an immunotherapy trial. The checkpoint inhibitor MED1476, the checkpoint inhibitor tremelimumab are given singly or in combination in patients who have progressed after standard chemotherapy. Open/Active Thomas Lowe, M.D.
Lymphoma Cancer Gilead GS-US-313-0124 iNHL A Phase 3, randomized stud of GS-1101 (CAL-101) in combination with rituximab for previously treated Indolent Non-Hodgkin Lymphoma. This study tests an oral drug combined with an antibody in patients with low grade lymphoma. Open/Active Hugo Hool, M.D.
Lymphoma Cancer Pfizer B3281006. A first line study using a biosimilar antibody of rituximab as immunotherapy for low grade follicular lymphoma. Open/Active Hugo Hool, M.D.
Bladder Cancer Lilly I4T-MC-JVDC Bladder A Phase 3, randomized study of ramucirumab plus docetaxel in patients with locally advanced or unresectable or metastatic urothelial carcinoma who progressed on or after platinum-based combination chemotherapy. Open/Active Thomas Lowe, M.D.
Prostate Cancer Hypo-fractionated Stereotactic Body Radiotherapy for Localized Prostate Cancer (NCT01059513) A study to obtain quality of life data after a hypo-fractionated course of stereotactic body radiation therapy (SBRT). Open/Active Bryan Chang, M.D.

For More Information

For more information about the clinical trials at Torrance Memorial, call 310-517-7077.